Intervention

Aromatase Inhibition Therapy

ClinicalTrials.gov intervention label

Clinical trials4
Recruiting1
Common conditions22
Lead sponsors shown3

Clinical trials

4 shown
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast CancerNCT06534125 · 2024-12-12
RECRUITING
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18
COMPLETED
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast CancerNCT01293032 · 2011-04-01
COMPLETED
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerNCT00005970 · 2000-05-19
COMPLETED

Common conditions

Hormone Receptor-Positive Breast Carcinoma2Stage IB Breast Cancer AJCC v72Stage IIA Breast Cancer AJCC v6 and v72Stage IIB Breast Cancer AJCC v6 and v72Stage IIIA Breast Cancer AJCC v72Anatomic Stage I Breast Cancer AJCC v81Anatomic Stage II Breast Cancer AJCC v81Anatomic Stage III Breast Cancer AJCC v81Breast Adenocarcinoma1Ductal Breast Carcinoma in Situ1HER2 Positive Breast Carcinoma1HER2-Negative Breast Carcinoma1HER2-Positive Breast Carcinoma1Lobular Breast Carcinoma in Situ1Stage IA Breast Cancer AJCC v71Stage II Breast Cancer1Stage IIA Breast Cancer1Stage IIB Breast Cancer1Stage IIIA Breast Cancer1Stage IIIB Breast Cancer1Stage IIIB Breast Cancer AJCC v71Stage IIIC Breast Cancer AJCC v71

Trial status mix

COMPLETED3
RECRUITING1

Phase mix

NA2
PHASE32

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.